Consistently with the literature, KRAS mutations predominated among the different appendiceal lesions: in fact, half of our cases showed KRAS point mutations and these mutations harboured in SSLs (about 60%) as well as in adenocarcinomas (44%). This evidence concerns the gene KRAS and adenocarcinoma.